血管内皮依赖性超极化因子的研究进展

内皮依赖性超极化因子（endothelium-dependent hyperpolarizing factor，EDHF）是血管平滑肌内皮源性舒张反应中通过非环氧合酶、非一氧化氮合酶途径的舒张因子。在不同物种、不同血管，EDHF反应都得到了确认。其在心血管生理学和药理学方面有着重要的作用。     

内皮依赖性超极化因子在剪切应力引起的内皮依赖性舒张反应中的作用

目的研究内皮依赖性超极化因子(EDHF)在剪切应力引起的内皮依赖性舒张反应中的作用及机制。方法测定不同流量下的血管内径及各种内皮依赖性舒张因子抑制剂、钾通道抑制剂、细胞色素P450单氧化酶抑制剂作用下的血管内径。结果剪切应力在大鼠肠系膜微动脉引起的舒张反应是内皮依赖性的,且在大的肠系膜动脉明显大于小阻力型肠系膜动脉。EDHF在上述两种动脉的内皮依赖性舒张反应中作用均明显大于NO,起主要作用。剪切应力引起的内皮依赖性舒张反应不受SKF525A的抑制，ChTx加apamin明显抑制了此舒张反应，TBA则几乎完全抑制此舒张反应。结论在剪切应力引起的内皮依赖性舒张反应中EDHF起主要作用，钾通道特别是K_Ca通道的激活为主要机制。     

内皮依赖性超极化因子在血管舒张中的作用

目的研究内皮依赖性超极化因子(EDHF)在血管舒张中的作用及机制。方法测定各种内皮依赖性舒张因子抑制剂、钾通道抑制因子、细胞色素P450单氧化酶抑制剂作用下的血管环张力。结果EDHF的血管舒张作用在大鼠肠系膜微动脉明显大于胸主动脉。一氧化氮(NO)合成受到慢性抑制时,胸主动脉的EDHF作用有增加趋势,在肠系膜微动脉投药后3 d和1周的EDHF作用明显增加。ChTx部分抑制、TBA明显抑制EDHF在肠系膜微动脉的舒张作用。结论EDHF在大鼠肠系膜微动脉的内皮依赖性舒张反应中起主要作用;在NO合成受抑制时其作用明显增加;其作用介导于K_Ca通道。     

内皮超极化因子的研究进展

内皮超极化因子（EDHF）是由内皮释放的NO和PGI_2以外的另一种舒张因子,它通过使平滑肌细胞膜超极化而舒张血管,是内皮依赖性血管松驰的第3种重要机制。EDHF可能是花生四烯酸的细胞色素P450代谢产物EET-s,乙酰胆碱、缓激肽等激动剂作用于内皮细胞,使细胞内游离钙浓度升高,合成和（或）释放EDHF,作用于平滑肌细胞膜,激活钙依赖性钾通道,使细胞膜超极化,抑制电压依赖性钙通道的开放,引起血管松弛。在大血管中NO-cGMP松弛机制可能占主导地位,并且抑制EDHF生成;而在阻力小血管,EDHF则可能是引起血管松弛的主要因素。     

血管内皮细胞超极化因子

内皮细胞释放多种重要的生物活性物质 ,调节血管张力、血液纤溶与凝血机制、脂蛋白代谢、免疫反应等重要生命过程。内皮细胞释放的超极化因子 (EDHF)是一类既不同于一氧化氮 (NO) ,也不同于前列环素 (PGI2 )的活性成分 ,可能是花生四烯酸的非前列腺素类代谢物或细胞色素P45 0 ,也可能是K+ 或H2 O2 。EDHF可激活钙依赖性钾通道 ,诱导平滑肌膜电位超极化 ,诱发内皮依赖性舒血管反应。在病理状态下 ,尤其是NO通路障碍时 ,EDHF通路发挥重要作用。因此深入研究EDHF的药理学特征已形成心血管学科的又一热点     

内皮依赖性超极化作用

通过对内皮依赖性松弛作用机制的探讨，作者指出，除一氧化氮外，另外一种不依赖于ｃＧＭＰ的内皮衍生的超极化因子参与内皮依赖性扩血管作用，其超极化及松弛作用的可能与钙依赖性钾通道的开放有关。除ＮＯ和前列环素外，Ｈ２Ｏ２，花生四烯酸的非ＰＧ类代谢物及细胞     

内皮源性超极化因子对内皮一氧化氮合酶基因表达的调节

目的　以内皮细胞产生NO的关键酶———eNOS(内皮一氧化氮合酶 )为研究目标 ,探讨外源性内皮源性超极化因子EDHF(EETs)对内皮细胞合成NO的影响。方法　在原代培养 3～ 4代以内的牛主动脉内皮细胞中 ,分别加入不同浓度 (5 0～ 2 0 0nmol·L-1)的 8,9 EET、11,12 EET、14 ,15 EET ,作用 1h后用不同的方法收获细胞。用WesternBlot以及NorthernBlot方法检测EETs对eNOS基因表达的影响 ;同时通过检测L [3 H] 精氨酸转化为L [3 H] 瓜氨酸的量研究EETs对NOS活性的影响。结果　显示 8,9 EET、11,12 EET、14 ,15 EET均呈浓度依赖性地增加eNOS蛋白质的表达 ,并提高eNOSmRNA表达水平以及NOS酶活性。结论　外源性EDHF对eNOS基因表达是一种正反馈调节作用 ,从而能够促进内皮细胞NO的产生 ,通过药物调节内皮表氧化酶进而促进eNOS基因表达可作为防治心血管疾病的新策略     

血管平滑肌内皮依赖性超极化:非一氧化氮合成酶产物的作用(英文)

The endothelium plays a fundamental role in the blood coagulation cascade and at the site of injury is important in the development, and sequela, of atheroma. It is also now firmly established that endothelial cells can produce both vasorelaxant and vasoconstrictor factors and thus directly influence vascular tone and blood flow. Prostacyelin and NO are both potent vasodilators, and endothelin is a highly potent 21 amino acid peptide vasoconstrictor, which have all been shown to be syn     

外源性血管内皮衍生超极化因子对脑缺血再灌注损伤的影响

目的:硫化氢(hydrogen sulfide,H2S)为一种假定的血管内皮衍生超极化因子(endothelium-derived hyperpolarizing factor,EDHF),本研究探讨外源性H2S,即外源性假定的EDHF对脑缺血再灌注损伤的影响。方法:采用线栓法复制大鼠局灶性脑缺血(MCAO)再灌注损伤模型,测定动物行为功能、脑组织梗死体积、脑组织含水量、血清乳酸脱氢酶(LDH)活性及丙二醛(MDA)含量,用HE染色法观察脑组织学改变。结果:H2S供体硫氢化钠(NaHS,i.v.)0.195、0.390、0.780mg/kg能明显改善神经功能状态,降低缺血再灌注后脑梗死体积百分比,降低脑含水量,显著地抑制局灶性脑缺血再灌注损伤大鼠血清MDA含量和LDH活性,并不同程度地改善大鼠脑病理组织学的变化。结论:NaHS可明显改善大鼠脑缺血再灌注性损伤,提示外源性ED-HF(H2S)有抗脑缺血再灌损伤作用。     

Characterization of cannabinoid receptors coupled to vasorelaxation by endothelium-derived hyperpolarizing factor

We have recently proposed that an endogenous cannabinoid may be an endothelium-derived hyperpolarizing factor (EDHF), and we have now characterized the cannabinoid receptors mediating these responses. EDHF-mediated vasorelaxations to carbachol (ED₅₀=3.26±0.57 nmol; the maximum relaxation, R _max=87.0±2.5%) were opposed by the selective cannabinoid CB₁ antagonist, LY320135: at 2 μM ED₅₀ for carbachol was 10.4±2.6 nmol and R _max was 66.9±6.2%, at 10 μM ED₅₀ was 15.9±4.0 nmol and R _max was 34.0±4.3%. However, these responses were unaffected by another putative CB₁ ligand, AM630 (10 μM), or a CB₂ selective antagonist, SR144528 (100 nM–1 μM). None of the antagonists influenced vasorelaxation to either the potassium channel activator levcromakalim or sodium nitroprusside. Coupled to our previous observation that the CB₁ receptor antagonist SR141716A opposes EDHF-mediated relaxation, the present observations point to the involvement of a cannabinoid receptor, which may be CB₁ or CB₁-like, in EDHF-mediated vasorelaxation. Received: 6 July 1998 / Accepted: 2 October 1998     

Specific impairment of endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from streptozotocin-induced diabetic mice

We hypothesized that the contribution made by endothelium-derived hyperpolarizing factor (EDHF) to acetylcholine (ACh)-induced endothelium-dependent relaxation (EDR) might be altered in mesenteric arteries from streptozotocin (STZ)-induced diabetic mice. In endothelium-intact preparations, the ACh-induced EDR (but not the sodium nitroprusside-induced relaxation) was weaker in the STZ group than in age-matched controls. Indomethacin (10 muM) had no significant effect on EDR in either group, indicating that cyclooxygenase products, including prostacyclin, are not involved. This indomethacin-resistant EDR was weaker in the STZ group than in the controls. To isolate the EDHF-resistant component of EDR, charybdotoxin (100 nM) and apamin (100 nM) were present in the bath solution throughout the next experiment. This EDHF-resistant relaxation did not differ significantly between the two groups. On the other hand, the EDHF-mediated relaxation was significantly weaker in the STZ group than in the controls, and it was completely blocked by lysophosphatidylcholine (LPC, 10 microM) in each group. The eNOS protein expression was similar between the two groups. These results suggest that (a) the endothelial dysfunction present in mesenteric arteries from type 1 diabetic mice is largely attributable to reduced EDHF signaling, and (b) LPC may be involved in this attenuation of EDHF-mediated relaxation.     

Flow-induced enhancement of vasoconstriction and blockade of endothelium-derived hyperpolarizing factor (EDHF) by ascorbate in the rat mesentery

BACKGROUND AND PURPOSE: We previously reported that ascorbate inhibits flow- and agonist-induced, EDHF-mediated vasodilatation in the bovine ciliary circulation. This study examined whether ascorbate had similar actions in the rat mesenteric vasculature. EXPERIMENTAL APPROACH: The effects of ascorbate were examined both in rat second order mesenteric arterial rings suspended in a static wire myograph and the rat mesentery perfused at different rates of flow. KEY RESULTS: Ascorbate (50 microM) had no effect on U46619-induced tone or acetylcholine-induced, EDHF-mediated vasodilatation in either rings of mesenteric artery or the perfused mesentery at rates of flow below 10 ml min(-1). At higher rates of flow, ascorbate produced two distinct effects in the rat mesentery: a rapid and maintained enhancement of vasoconstrictor tone and a slow (max at 3 h) inhibition of acetylcholine-induced, EDHF-mediated vasodilatation. The enhancement of vasoconstrictor tone appeared to be due to inhibition of flow-induced EDHF-like activity, since it was endothelium-dependent, but could be elicited during blockade of nitric oxide synthase and cyclooxygenase. Despite this, the classical inhibitors of EDHF, apamin and charybdotoxin, failed to affect the ascorbate-induced enhancement of tone, although they inhibited acetylcholine-induced vasodilatation. CONCLUSIONS AND IMPLICATIONS: Ascorbate inhibits both flow- and agonist-induced EDHF in the rat mesentery. The strikingly different timecourses of these two effects, together with their differential sensitivity to apamin and charybdotoxin, suggest that the flow- and agonist-induced EDHFs in the rat mesenteric vasculature may either be different entities or operate by different mechanisms.     

The significance of endothelium-derived hyperpolarizing factor in the human circulation

Although nitric oxide (NO) is recognized as the primary vasodilator derived from vascular endothelium in regulating the vascular tone, another factor, i.e. the endothelium-derived hyperpolarizing factor (EDHF), has recently gained much attention and has been demonstrated to participate in vasodilatation in various blood vessels from different species, despite its unidentified nature. Most of the studies were conducted in animals and the knowledge of this factor in the human vasculature is relatively limited. This review attempts to address the relevance of EDHF-mediated function in humans with the possible identity of EDHF and mechanisms involved. We consider the human vasculature where EDHF involvement has been documented including the systemic, coronary, and visceral (gastrointestinal, renal and reproductive) circulation. In these vascular systems, EDHF plays a role under physiological conditions either as another mechanism or as the "back-up" for NO. Furthermore, the contribution of EDHF changes under certain physiological conditions, such as ageing and pregnancy. In addition, altered EDHF function has been suggested in various pathological conditions including heart diseases, atherosclerosis, hypertension, diabetes, eclampsia, glaucoma, chronic renal failure, erectile dysfunction and ischemia-reperfusion period during open heart surgery. Pharmacological agents such as potassium channel openers or cytochrome P450 metabolites have been used to either protect or recover EDHF-dependent mechanisms. To further develop new therapeutic strategies that target EDHF, a better understanding is essential with regard to the function of EDHF under pathophysiological conditions in humans. Furthermore, the interaction between NO and EDHF as well as their relative contributions in various conditions are critical.     

BAY 41-2272, a potent activator of soluble guanylyl cyclase, stimulates calcium elevation and calcium-activated potassium current in pituitary GH cells

The effects of BAY 41-2272, a nitric oxide-independent activator of soluble guanylyl cyclase, on Ca2+ signalling and ion currents were investigated in pituitary GH3 cells. Intracellular Ca2+ concentrations ([Ca2+]i) in these cells were increased by BAY 41-2272. Removing extracellular Ca2+ abolished the BAY 41-2272-induced increase in [Ca2+]i. After [Ca2+]i was elevated by BAY 41-2272 (300 nmol/L), subsequent application of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl) indazole (YC-1; 1 micromol/L) did not increase [Ca2+]i further. In whole-cell recordings, BAY 41-2272 reversibly stimulated Ca2+-activated K+ current (I(K(Ca))) with an EC50 of 225 +/- 8 nmol/L. At 3 micromol/L, BAY 41-2272 slightly and significantly decreased L-type Ca2+ current.In the cell-attached configuration, BAY 41-2272 (300 nmol/L) enhanced the activity of large-conductance Ca2+-activated K+ (BK(Ca)) channels. After BK(Ca) channel activity was stimulated by spermine NONOate (30 micromol/L) or YC-1 (10 micromol/L) in cell-attached patches, subsequent application of BAY 41-2272 (300 nmol/L) further increased the channel open probability. In the inside-out configuration, BAY 41-2272 applied to the intracellular surface of excised patches enhanced BK(Ca) channel activity. Unlike 1 micromol/L paxilline, 1H-[1,2,4]oxadiazolol-[4,3a] quinoxalin-1-one (ODQ; 10 micromol/L) or heme (10 micromol/L) had no effect on BAY 41-2272-stimulated channel activity. BAY 41-2272 caused no shift in the activation curve of BK(Ca) channels; however, it did increase the Ca2+ sensitivity of these channels. At 300 nmol/L, BAY 41-2272 reduced the firing rate of spontaneous action potentials stimulated by thyrotropin-releasing hormone (10 micromol/L). The BK(Ca) channel activity was also enhanced by 300 nmol/L BAY 41-2272 in neuroblastoma IMR-32 cells. Therefore, the BAY 41-2272-induced increase in [Ca2+]i is primarily explained by an increase in Ca2+ influx. The BAY 41-2272-mediated simulation of IK(Ca) may result from direct activation of BKCa channels and indirectly as a result of elevated [Ca2+]i.     

糖尿病大鼠冠状动脉平滑肌细胞中大电导钙离子激活钾通道电流和钙离子浓度变化

目的探讨糖尿病大鼠冠状动脉平滑肌细胞中大电导钙离子激活钾通道(BK通道)电流及钙离子浓度的变化。方法 40只SD大鼠随机均分为正常对照组(A组)和糖尿病组(B组)。采用链脲霉素腹腔内注射建立糖尿病大鼠模型,酶消化法分离冠状动脉平滑肌细胞,全细胞膜片钳实验和荧光测定方法分别检测冠状动脉平滑肌细胞BK通道电流和钙离子浓度。结果与A组相比,当刺激电压大于60mV时,B组冠状动脉平滑肌细胞BK通道电流密度明显下降(P<0.05);A组冠状动脉平滑肌细胞内钙离子浓度明显低于B组[(103±23)nmol/L vs.(193±22)nmol/L](P<0.05)。结论冠状动脉平滑肌细胞中BK通道电流下降及细胞内钙离子浓度升高可能是糖尿病冠状动脉功能损伤的重要原因。